Skip to content

A modeling predictive study of clinical factors associated with lithium on treatment responsiveness in patients with bipolar disorder

A modeling predictive study of clinical factors associated with lithium on treatment responsiveness in patients with bipolar disorder

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500099510
Enrollment
Unknown
Registered
2025-03-25
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bipolar disorder

Interventions

Lithium Good Response group:None
Lithium Partial Response group:None
Lithium Non-Response group:Nobe

Sponsors

Second xiangya hospital of central south university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
10 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Satisfy the criteria of Diagnostic and Statistical Manual of Mental Disorders (5th edition) for bipolar I or II disorder or major depression or major mania; 2. Age: 10-65 years old; 3. First treatment with lithium carbonate or more than 6 months since the last treatment with lithium carbonate; 4. More than 1 blood concentration monitoring during hospitalization for lithium carbonate treatment.

Exclusion criteria

Exclusion criteria: 1.Incomplete data on patients' blood levels, basic clinical characteristics and biochemical indicators; 2. Female patients are pregnant and breastfeeding; 3. Discontinuation of treatment due to significant adverse reactions following the use of lithium carbonate.

Design outcomes

Primary

MeasureTime frame
Lithium Ion Blood Concentration;Years of lithium carbonate use, number of seizures prior to lithium carbonate use, frequency of seizures prior to lithium carbonate use, combination with lithium carbonate use;

Secondary

MeasureTime frame
Demographic characteristics (age, sex, days in hospital, weight, BMI);Dosing patterns (time of dosing, number of doses, starting dose, combinations, days at starting dose, maintenance dose, days at maintenance dose, final dose);

Countries

China

Contacts

Public ContactCai Hualin

Department of Pharmacy, The Second Xiangya Hospital of Central South University, No. 139, Renmin Middle Road, Furong District, Changsha, Hunan, China

hualincai@csu.edu.cn+86 137 5508 7574

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026